zilucoplan

Details

Generic Name:
zilucoplan
Project Status:
Pending
Therapeutic Area:
Generalized myasthenia gravis (gMG)
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0838-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the treatment of refractory gMG in adult patients who are AChR antibody positive, and not achieving symptom control after: an adequate trial of two or more immunosuppressive therapies (ISTs), either in combination or as a monotherapy in the previous 12 months, OR at least one IST and chronic plasmapheresis, plasma exchange (PLEX) or intravenous immunoglobulin (IVIg)
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​For the for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.